Abstract Library

#4507 Biliary complications for metastatic patients with neuroendocrine tumours of the pancreatic head and their influence on survival: Is it necessary to change the current management?

Introduction: Neuroendocrine tumours of the pancreatic head (NETPH) can be associated with local complications. At the metastatic stage, surgery of the primary tumour (PT) is not a standard of care. But the biliary complications (BC) due to the untreated NETPH may complicate the management and deteriorate the prognosis.

Conference:

Presenting Author: Ujlaki G

Authors: Ujlaki G, Fernandez de Sevilla E, Moog S, Lamartina L, Hadoux J,

Keywords: neuroendocrine, pancreatic head, metastatic, biliary complications,

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,

#4322 Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10mm after endoscopic resection

Introduction: Rectal neuroendocrine tumours (r-NETs) generally have a good prognosis, but up to 20% may be misdiagnosed during endoscopy, risking inadequate treatment. Prognosis factors include tumour size, grading, staging, and lymphovascular invasion, with guidelines recommending endoscopic resection for small, low-grade lesions.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Panzuto F, Luong T,

Keywords: Rectal Carcinoid, Rectal Neuroendocrine Tumour, Endoscopic Resection,

#4315 The indolent nature of type 1 gastric neuroendocrine tumours under 1cm: Insights from a dual-centre study

Introduction: Current guidelines primarily recommend endoscopic surveillance for type 1 gastric neuroendocrine tumours (g-NETs) measuring ≤10mm, though these guidelines are largely based on expert consensus rather than strong evidence.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Rinzivillo M, Esposito G,

Keywords: Gastric Neuroendocrine Tumour, Carcinoid, Endoscopic Surveillance,

#4186 The effect of the Covid-19 pandemic on the body composition of patients with gastroenteropancreatic neuroendocrine tumors using a somatostatin analogue

Introduction: The Covid-19 pandemic and its restrictions had a negative impact on the general population. Due to lockdowns, food intake increased and exercise decreased. This led to weight gain and changes in body composition. Hospitals reviewed patients (pts) remotely. The effect of the Covid-19 pandemic has not been described in pts with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogue (SSA).

Conference:

Presenting Author: Clement D

Authors: Clement D, Brown S, Dolly S, Mestre-Alagarda C, Giovos G,

Keywords: GEP-NET, SSA, malnutrition, Covid-19 pandemic,